News articles about FibroGen (NASDAQ:FGEN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. FibroGen earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.5632448049908 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
FibroGen (FGEN) traded up $1.15 during midday trading on Wednesday, reaching $54.25. 534,500 shares of the company’s stock traded hands, compared to its average volume of 605,643. The stock has a market cap of $4,364.69, a PE ratio of -27.48 and a beta of 1.74. FibroGen has a fifty-two week low of $22.75 and a fifty-two week high of $63.00. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.
FGEN has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Mizuho reiterated a “hold” rating and issued a $61.00 target price on shares of FibroGen in a research note on Thursday, November 9th. Four research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $65.67.
In related news, insider K Peony Yu sold 7,500 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $53.97, for a total transaction of $404,775.00. Following the transaction, the insider now owns 144,986 shares of the company’s stock, valued at approximately $7,824,894.42. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $46.60, for a total transaction of $880,740.00. Following the transaction, the chief executive officer now directly owns 3,109,555 shares in the company, valued at approximately $144,905,263. The disclosure for this sale can be found here. Insiders sold a total of 318,417 shares of company stock worth $15,733,466 in the last three months. Insiders own 13.60% of the company’s stock.
WARNING: “FibroGen (FGEN) Earns Media Sentiment Score of 0.19” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/fibrogen-fgen-earns-daily-news-sentiment-score-of-0-19.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.